Table 2.
n | Success rate | Percentage | 95% CI | P | |
---|---|---|---|---|---|
Salvaged | 13 | - | 46 | 0.2953-0.6419 | - |
Enucleated | 15 | - | - | 0.3581-0.7047 | - |
Male | 14 | 8 | 57 | 0.3255-0.7866 | 1.00 |
Female | 10 | 5 | 50 | 0.2366-0.7634 | |
Bilateral | 20 patients, 24 eyes | 12 | 50 | 0.3143-0.6857 | |
Unilateral | 4 | 1 | 25 | 0.0341-0.7109 | |
Right eye | 13 | 8 | 61 | 0.3541-0.8240 | 0.1228 |
Left eye | 15 | 5 | 33 | 0.1496-0.5850 | |
No vitreous seeds | 10 | 9 | 90 | 0.5740->0.9999 | 0.0011 |
Vitreous seeds | 18 | 4 | 22 | 0.0847-0.4575 | |
IIRC (B, C) | 10 | 7 | 70 | 0.3923-0.8967 | 0.1141 |
IIRC D | 18 | 6 | 33 | 0.1610-0.5643 | |
RE (I-IV) | 6 | 4 | 67 | 0.2957-0.9075 | 0.6703 |
RE V | 22 | 9 | 4 | 0.2321-0.6131 | |
RE Va | 6 | 5 | 83 | 0.4178-0.9886 | 0.0464 |
RE Vb | 16 | 4 | 25 | 0.0971-0.4997 | |
No Stage migration 9 (B, C) | 6 | 6 | 100 | 0.5572-1.0000 | 0.0333 |
Stage migration (B, C) | 4 | 1 | 25 | 0.0341-0.7109 | |
8 cycles of CVE | 14 | 7 | 50 | 0.2680-0.7320 | 1.00 |
6 cycles CVE | 14 | 6 | 43 | 0.2134-0.6745 |